Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients

详细信息    查看全文

• 作者：Tilman Todenhöfer ; Jörg Hennenlotter…
• 关键词：AdnaTest ; Biomarker ; Bladder cancer ; Circulating tumor cells
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：142
• 期：5
• 页码：1013-1020
• 全文大小：642 KB
• 参考文献：Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11(4):R46. doi:10.​1186/​bcr2333 CrossRef PubMed PubMedCentral
  Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, Premasekharan G, Tran T, Fu C, Ionescu-Zanetti C, Schwartz M, Fan A, Paris P (2015) Circulating tumor cells as potential biomarkers in bladder cancer. J Urol. doi:10.​1016/​j.​juro.​2015.​02.​2951 PubMed
  Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M (2012) Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer select/detect versus veridex cell search system. Int J Cancer 130(7):1590–1597. doi:10.​1002/​ijc.​26111 CrossRef PubMed
  Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl J Med 371(11):1028–1038. doi:10.​1056/​NEJMoa1315815 CrossRef PubMed PubMedCentral
  Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ (2014a) Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11(7):400–410. doi:10.​1038/​nrurol.​2014.​129 CrossRef PubMed
  Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ (2014b) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152–165. doi:10.​1016/​j.​ccr.​2014.​01.​009 CrossRef PubMed PubMedCentral
  Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111(8):3110–3115. doi:10.​1073/​pnas.​1318376111 CrossRef PubMed PubMedCentral
  Engilbertsson H, Aaltonen KE, Bjornsson S, Kristmundsson T, Patschan O, Ryden L, Gudjonsson S (2015) Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol 193(1):53–57. doi:10.​1016/​j.​juro.​2014.​06.​083 CrossRef PubMed
  Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579):472–476. doi:10.​1038/​nature15748 CrossRef PubMed
  Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, Genova EE, Morales D, Lucia MS (2011) Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 78(4):863–867. doi:10.​1016/​j.​urology.​2011.​05.​045 CrossRef PubMed PubMedCentral
  Gazzaniga P, Nofroni I, Gandini O, Silvestri I, Frati L, Agliano AM, Gradilone A (2005) Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. Oncol Rep 14(5):1199–1202PubMed
  Hayashi T, Seiler R, Oo HZ, Jager W, Moskalev I, Awrey S, Dejima T, Todenhofer T, Li N, Fazli L, Matsubara A, Black PC (2015a) Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over-expressing bladder cancer. J Urol. doi:10.​1016/​j.​juro.​2015.​05.​087 PubMed
  Hayashi T, Seiler R, Oo HZ, Jager W, Moskalev I, Awrey S, Dejima T, Todenhofer T, Li N, Fazli L, Matsubara A, Black PC (2015b) Targeting HER2 with T-DM1, an Antibody-cytotoxic Drug Conjugate, is effective in HER2-overexpressing bladder cancer. J Urol. doi:10.​1016/​j.​juro.​2015.​05.​087 PubMed
  Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC, National Cancer I (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25(16):2218–2224. doi:10.​1200/​JCO.​2006.​08.​0994 CrossRef PubMed
  Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan B, Trautwein J, Barber TA, Stott SL, Maheswaran S, Kapur R, Haber DA, Toner M (2014) Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 9(3):694–710. doi:10.​1038/​nprot.​2014.​044 CrossRef PubMed PubMedCentral
  Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T (2012) Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 14(1):R15. doi:10.​1186/​bcr3099 CrossRef PubMed PubMedCentral
  Liu H, Zhang X, Li J, Sun B, Qian H, Yin Z (2015) The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol 141(2):189–201. doi:10.​1007/​s00432-014-1752-x CrossRef PubMed
  Msaouel P, Koutsilieris M (2011) Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer 11:336CrossRef PubMed PubMedCentral
  Muller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Group DS (2012) Prognostic impact of circulating tumor cells assessed with the Cell Search System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 14(4):R118. doi:10.​1186/​bcr3243 CrossRef PubMed PubMedCentral
  Ning Y, Zhang W, Hanna DL, Mendez A, Yang D, Sunakawa Y, Stremitzer S, Matsusaka S, Okazaki S, Parekh A, El-Khoueiry RE, Flores B, Hauch S, Barzi A, El-Khoueiry AB, Lenz H-J (2015) Circulating tumor cell (CTC) EMT and stem cell biomarker expression predict overall survival (OS) in mCRC by a combined immunomagnetic qRT-PCR approach. ASCO Meeting Abstr 33(15_suppl):11018
  Oudard S, Culine S, Vano Y, Goldwasser F, Theodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P (2015) Multicentre randomised phase II trial of gemcitabine + platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer 51(1):45–54. doi:10.​1016/​j.​ejca.​2014.​10.​009 CrossRef PubMed
  Pantel K, Alix-Panabieres C (2012) The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov 2(11):974–975. doi:10.​1158/​2159-8290.​CD-12-0432 CrossRef PubMed
  Ribal MJ, Mengual L, Marin M, Algaba F, Ars E, Fernandez PL, Oliva R, Villavicencio H, Alcaraz A (2006) Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: comparison with standard histological staging. Anticancer Res 26(1A):411–419PubMed
  Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64(11):937–946. doi:10.​1136/​jcp.​2011.​090456 CrossRef PubMed
  Rink M, Chun FK, Minner S, Friedrich M, Mauermann O, Heinzer H, Huland H, Fisch M, Pantel K, Riethdorf S (2011) Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int 107(10):1668–1675. doi:10.​1111/​j.​1464-410X.​2010.​09562.​x CrossRef PubMed
  Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, Shariat SF, Fisch M, Pantel K, Riethdorf S (2012) Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 61(4):810–817. doi:10.​1016/​j.​eururo.​2012.​01.​017 CrossRef PubMed
  Stojnev S, Ristic-Petrovic A, Velickovic LJ, Krstic M, Bogdanovic D, Khanh do T, Ristic A, Conic I, Stefanovic V (2014) Prognostic significance of mucin expression in urothelial bladder cancer. Int J Clinical Exp Pathol 7(8):4945–4958
  Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115(3):581–590. doi:10.​1007/​s10549-008-0143-x CrossRef PubMed
  Tinhofer I, Saki M, Niehr F, Keilholz U, Budach V (2014) Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol 90(8):622–627. doi:10.​3109/​09553002.​2014.​886798 CrossRef PubMed
  Todenhofer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kuhs U, Gerber V, Fetisch J, Schilling D, Hauch S, Stenzl A, Schwentner C (2012) Preliminary experience on the use of the Adnatest(R) system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res 32(8):3507–3513PubMed
  Tvrdik D, Stanek L, Skalova H, Dundr P, Velenska Z, Povysil C (2012) Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Mol Med Rep 6(2):439–443. doi:10.​3892/​mmr.​2012.​919 PubMed
  Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DA (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345(6193):216–220. doi:10.​1126/​science.​1253533
  
• 作者单位：Tilman Todenhöfer (1)
  Jörg Hennenlotter (1)
  Nathalie Dorner (1)
  Ursula Kühs (1)
  Stefan Aufderklamm (1)
  Steffen Rausch (1)
  Simone Bier (1)
  Johannes Mischinger (1)
  Doreen Schellbach (2)
  Siegfried Hauch (2)
  Natalie Feniuk (2)
  Jens Bedke (1)
  Georgios Gakis (1)
  Arnulf Stenzl (1)
  Christian Schwentner (1)
  
  1. Department of Urology, University Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany
  2. Qiagen Hannover, Langenhagen, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  Internal Medicine
  Hematology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1335

文摘

Purpose There is increasing interest in circulating tumor cells (CTCs) as a biomarker in bladder cancer (BC). In the present pilot study, we used a platform originally developed for detection of breast cancer CTCs to assess breast cancer-associated transcripts in CTCs of patients with different stages of BC. Moreover, transcripts specific for cancer stem cells and epithelial mesenchymal transition (EMT) were assessed.